Evidence map›Paper›PMID 31098000›Full record

ArticleACS medicinal chemistry letters2019

Discovery of CDK5 Inhibitors through Structure-Guided Approach.

Nishat Z Khair, Jimma L Lenjisa, Solomon Tadesse, Malika Kumarasiri, Sunita K C Basnet, Laychiluh B Mekonnen, Manjun Li, Sarah Diab, Matthew J Sykes, Hugo Albrecht and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. A patent review of cyclin-dependent kinase 5 (CDK5) inhibitors (1999-2025).Frontiers in bioengineering and biotechnology · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Nishat Z KhairCentre for Drug Discovery and Development, School of Pharmacy and Medical Sciences, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.
Jimma L LenjisaCentre for Drug Discovery and Development, School of Pharmacy and Medical Sciences, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.
Solomon TadesseCentre for Drug Discovery and Development, School of Pharmacy and Medical Sciences, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.
Malika KumarasiriCentre for Drug Discovery and Development, School of Pharmacy and Medical Sciences, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.
Sunita K C BasnetCentre for Drug Discovery and Development, School of Pharmacy and Medical Sciences, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.
Laychiluh B MekonnenCentre for Drug Discovery and Development, School of Pharmacy and Medical Sciences, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.
Manjun LiCentre for Drug Discovery and Development, School of Pharmacy and Medical Sciences, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.
Sarah DiabCentre for Drug Discovery and Development, School of Pharmacy and Medical Sciences, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.
Matthew J SykesCentre for Drug Discovery and Development, School of Pharmacy and Medical Sciences, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.
Hugo AlbrechtCentre for Drug Discovery and Development, School of Pharmacy and Medical Sciences, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.
Robert MilneCentre for Drug Discovery and Development, School of Pharmacy and Medical Sciences, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.
Shudong WangCentre for Drug Discovery and Development, School of Pharmacy and Medical Sciences, Cancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.
University of South Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Specific abrogation of cyclin-dependent kinase 5 (CDK5) activity has been validated as a viable approach for the development of anticancer agents. However, no selective CDK5 inhibitor has been reported to date. Herein, a structure-based

Identifiers

PMID31098000
PMCPMC6511963
OpenAlexW2924459278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.